Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMY ) 9.670 +0.020 (+0.21%) Streaming Delayed Price Updated: 3:58 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 369,694 Open 9.410 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 9.650 Today's Range 9.410 - 9.730 52wk Range 9.150 - 13.14 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst October 29, 2024 It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. Via The Motley Fool Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch October 16, 2024 William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... Via Benzinga Performance YTD -18.26% -18.26% 1 Month -6.03% -6.03% 3 Month -18.53% -18.53% 6 Month -1.93% -1.93% 1 Year -19.88% -19.88% More News Read More 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Via Investor's Business Daily Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data August 05, 2024 Via Benzinga MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential February 22, 2024 Via Talk Markets Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal December 31, 2023 Via Talk Markets Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 Via Benzinga How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks October 22, 2023 Via Investor's Business Daily Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study October 05, 2023 Via Benzinga Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years September 24, 2023 Via The Motley Fool Why Is Seagen Stock Trading Higher Today? September 22, 2023 Via Benzinga Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer September 22, 2023 Via Investor's Business Daily What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? September 20, 2023 Via Benzinga How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? September 01, 2023 Via MarketBeat Topics Economy Exposures Interest Rates Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin August 07, 2023 Via Investor's Business Daily From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs July 07, 2023 Via Benzinga Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas June 17, 2023 Via Talk Markets Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles June 08, 2023 Via Benzinga The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Via Investor's Business Daily Why Shares of Annexon Are Plummeting Thursday May 25, 2023 Via The Motley Fool Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories May 15, 2023 Via Benzinga Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback May 15, 2023 Via Benzinga Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today May 01, 2023 Via The Motley Fool Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% May 01, 2023 Via Benzinga Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma May 01, 2023 Via Investor's Business Daily Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
